The Tumor Burden Score: A New "metro-ticket" Prognostic Tool for Colorectal Liver Metastases Based on Tumor Size and Number of Tumors

Annals of Surgery

Volumn 267, Issue 1, 2018, Pages 132-141

  Sasaki, Kazunari ^a   Morioka, Daisuke ^b   Conci, Simone ^c   Margonis, Georgios A ^a   Sawada, Yu ^b   Ruzzenente, Andrea ^c   Kumamoto, Takafumi ^b   Iacono, Calogero ^c   Andreatos, Nikolaos ^a   Guglielmi, Alfredo ^c   Endo, Itaru ^b   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

Colorectal liver metastases; liver resection; surgical outcomes; tumor morphology

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; FEMALE; HUMAN; LIVER LOBECTOMY; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; METRO TICKET PROGNOSTIC TOOL; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL HEPATECTOMY; PREOPERATIVE CHEMOTHERAPY; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RECEIVER OPERATING CHARACTERISTIC; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SEGMENTECTOMY; SURVIVAL ANALYSIS; SURVIVAL PREDICTION; SURVIVAL TIME; TUMOR VOLUME; AGED; CANCER STAGING; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; FOLLOW UP; LIVER RESECTION; LIVER TUMOR; METASTASIS; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SECONDARY;

AGED; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR BURDEN;

EID: 84992036354     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000002064     Document Type: Article

References (51)

1. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677-3683.
2. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759-766.
3. House MG, Ito H, Gonen M, et al. Survival after hepatic resection for metastatic colorectal cancer: Trends in outcomes for 1, 600 patients during two decades at a single institution. J Am Coll Surg. 2010;210:744-752.
4. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-318 [discussion 318-321].
5. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinomametastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77:1254-1262.
6. Kattan MW, Gonen M, Jarnagin WR, et al. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg. 2008;247:282-287.
7. Hughes KS, Rosenstein RB, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long-term survivors. Dis Colon Rectum. 1988;31:1-4.
8. Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg. 1995;19:59-71.
9. Gayowski TJ, Iwatsuki S, Madariaga JR, et al. Experience in hepatic resection for metastatic colorectal cancer: Analysis of clinical and pathologic risk factors. Surgery. 1994;116:703-710 [discussion 710-711].
10. Pawlik TM, Choti MA. Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases. Curr Oncol Rep. 2007;9:193-201.
11. Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist. 2008;13:51-64.
12. Conrad C, You N, Vauthey JN. In patients with colorectal liver metastases, can we still rely on number to define treatment and outcome Oncology (Williston Park). 2013;27:1078. 1083-1074, 1086.
13. Ekberg H, Tranberg KG, Andersson R, et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg. 1986;73:727-731.
14. Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: Is there a possibility of cure J Clin Oncol. 2009;27:1829-1835.
15. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38-47.
16. Ye LC, Liu TS, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liverlimited metastases. J Clin Oncol. 2013;31:1931-1938.
17. Gomez D, Cameron IC. Prognostic scores for colorectal liver metastasis: Clinically important or an academic exercise HPB (Oxford). 2010;12:227-238.
18. Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: Review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283-301.
19. Pawlik TM, Abdalla EK, Ellis LM, et al. Debunking dogma: Surgery for four or more colorectal liver metastases is justified. J Gastrointest Surg. 2006;10:240-248.
20. Nathan H, de Jong MC, Pulitano C, et al. Conditional survival after surgical resection of colorectal liver metastasis: An international multi-institutional analysis of 949 patients. J Am Coll Surg. 2010;210:755-764.
21. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: A bad idea. Stat Med. 2006;25:127-141.
22. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
23. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394-1403.
24. Decaens T, Roudot-Thoraval F, Hadni-Bresson S, et al. Impact of UCSF criteria according to pre-A nd post-OLT tumor features: Analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl. 2006;12:1761-1769.
25. Kaido T, Ogawa K, Mori A, et al. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery. 2013;154:1053-1060.
26. Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis. 2007;25:310-312.
27. Mazzaferro V. Results of liver transplantation: With or without Milan criteria Liver Transpl. 2007;13:S44-S47.
28. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. Lancet Oncol. 2009;10:35-43.
29. Strasberg SM. Nomenclature of hepatic anatomy and resections: A review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg. 2005;12:351-355.
30. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
31. Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550-558.
32. Hanley JA, Mc Neil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
33. Hanley JA, Mc Neil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843.
34. Akaike H. A new look at the statistical model identification. Automatic Control IEEE Transactions on. 1974;19:716-723.
35. Burnham KP, Anderson DR. Multimodel inference understanding AIC and BIC in model selection. Sociol Meth Res. 2004;33:261-304.
36. Margonis GA, Spolverato G, Kim Y, et al. Effect of KRAS mutation on longterm outcomes of patients undergoing hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2015;22:4158-4165.
37. Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258:619-626 [discussion 626-627].
38. Dexiang Z, Li R, Ye W, et al. Outcome of patients with colorectal liver metastasis: Analysis of 1, 613 consecutive cases. Ann Surg Oncol. 2012;19:2860-2868.
39. Malik HZ, Prasad KR, Halazun KJ, et al. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg. 2007;246:806-814.
40. Zakaria S, Donohue JH, Que FG, et al. Hepatic resection for colorectal metastases: Value for risk scoring systems Ann Surg. 2007;246:183-191.
41. Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: A proposal of a prognostic scoring system. J Am Coll Surg. 1999;189:291-299.
42. Beppu T, Sakamoto Y, Hasegawa K, et al. A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: Multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2012;19:72-84.
43. Kanemitsu Y, Kato T. Prognostic models for predicting death after hepatectomy in individuals with hepatic metastases from colorectal cancer. World J Surg. 2008;32:1097-1107.
44. Konopke R, Kersting S, Distler M, et al. Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int. 2009;29:89-102.
45. Ayez N, Lalmahomed ZS, van der Pool AE, et al. Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy Ann Surg Oncol. 2011;18:2757-2763.
46. Tomlinson JS, Jarnagin WR, De Matteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25:4575-4580.
47. Castaing D, Vibert E, Ricca L, et al. Oncologic results of laparoscopic versus open hepatectomy for colorectal liver metastases in two specialized centers. Ann Surg. 2009;250:849-855.
48. Maithel SK, Gonen M, Ito H, et al. Improving the clinical risk score: An analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. Surgery. 2012;151: 162-170.
49. Merkel S, Bialecki D, Meyer T, et al. Comparison of clinical risk scores predicting prognosis after resection of colorectal liver metastases. J Surg Oncol. 2009;100:349-357.
50. Small RM, Lubezky N, Shmueli E, et al. Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy. J Surg Oncol. 2009;99:93-98.
51. John SK, Robinson SM, Rehman S, et al. Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: An 11-year single-centre study. Dig Surg. 2013;30:293-301.